Safety and Efficacy of Anlotinib-based Regimen in Patients with Unresectable or Metastatic Bone and Soft-tissue Sarcomas: A Retrospective Institutional Study


Cite item

Full Text

Abstract

Background:Anlotinib has demonstrated durable clinical benefits in patients with unresectable or metastatic bone and soft-tissue sarcomas.

Methods:92 patients treated with chemotherapy combined with or without anlotinib were collected and analyzed. The objective response rate (ORR) and disease control rate (DCR) were analyzed. Long-term survival was assessed using the Kaplan-Meier method, including median progression-free survival (mPFS) and overall survival (mOS).

Results:Liposarcoma, synovial sarcoma, and rhabdomyosarcoma were the primary pathological subtypes of the 92 patients. The median age was 46 (range, 11-75) years. The ORR and DCR of the anlotinib-chemotherapy combination used as first-line therapy were 31.9% and 85.1%, respectively. However, the ORR and DCR were only 6.7% and 57.8% in the chemotherapy alone, respectively. Compared with the chemotherapy group, improvements were observed in the mPFS and mOS with anlotinib-based regimen (mPFS, 8.3 vs. 3.0 months; mOS, 59.0 vs. 22.0 months). Anlotinib-associated adverse events were well tolerated and mainly occurred in grades I and II. New anlotinib-related adverse reactions were not noted.

Conclusion:Anlotinib-based regimen as a first-line therapy showed a positive effect on the treatment of unresectable or metastatic BSTSs. The anlotinib-associated adverse events were minor and well tolerated.

About the authors

Lina Pang

Department of Oncology, First Affiliated Hospital of Zhengzhou University

Email: info@benthamscience.net

Shengli Zhang

Department of Oncology, The First Affiliated Hospital of Zhengzhou University

Email: info@benthamscience.net

Liye Wang

Department of Oncology, The First Affiliated Hospital of Zhengzhou University

Email: info@benthamscience.net

Shuai Gong

Department of Oncology, The First Affiliated Hospital of Zhengzhou University

Email: info@benthamscience.net

Wei He

Department of Oncology, The First Affiliated Hospital of Zhengzhou University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Sbaraglia, M.; Bellan, E.; Dei Tos, A.P. The 2020 who classification of soft tissue tumours: News and perspectives. Pathologica, 2020, 113(2), 70-84. doi: 10.32074/1591-951X-213 PMID: 33179614
  2. Chi, Y.; Fang, Z.; Hong, X.; Yao, Y.; Sun, P.; Wang, G.; Du, F.; Sun, Y.; Wu, Q.; Qu, G.; Wang, S.; Song, J.; Yu, J.; Lu, Y.; Zhu, X.; Niu, X.; He, Z.; Wang, J.; Yu, H.; Cai, J. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin. Cancer Res., 2018, 24(21), 5233-5238. doi: 10.1158/1078-0432.CCR-17-3766 PMID: 29895706
  3. Yang, Z.; Zheng, R.; Zhang, S.; Zeng, H.; Li, H.; Chen, W. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol. Med., 2019, 16(3), 565-574. doi: 10.20892/j.issn.2095-3941.2019.0041 PMID: 31565485
  4. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30. doi: 10.3322/caac.21442 PMID: 29313949
  5. Whelan, J.S.; Davis, L.E. Osteosarcoma, chondrosarcoma, and chordoma. J. Clin. Oncol., 2018, 36(2), 188-193. doi: 10.1200/JCO.2017.75.1743 PMID: 29220289
  6. Riggi, N.; Suvà, M.L.; Stamenkovic, I. Ewing’s sarcoma. reply. N. Engl. J. Med., 2021, 384(15), 1477-1478. PMID: 33852794
  7. Singhi, E.; Moore, D.; Muslimani, A. Metastatic soft tissue sarcomas: A review of treatment and new pharmacotherapies. P T, 2018, 43(7), 410-429. PMID: 30013298
  8. Smrke, A.; Wang, Y.; Simmons, C. Update on systemic therapy for advanced soft-tissue sarcoma. Curr. Oncol., 2020, 27(11)(Suppl. 1), 25-33. doi: 10.3747/co.27.5475 PMID: 32174755
  9. Savina, M.; Le Cesne, A.; Blay, J.Y.; Ray-Coquard, I.; Mir, O.; Toulmonde, M.; Cousin, S.; Terrier, P.; Ranchere-Vince, D.; Meeus, P.; Stoeckle, E.; Honoré, C.; Sargos, P.; Sunyach, M.P.; Le Péchoux, C.; Giraud, A.; Bellera, C.; Le Loarer, F.; Italiano, A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: The METASARC observational study. BMC Med., 2017, 15(1), 78. doi: 10.1186/s12916-017-0831-7 PMID: 28391775
  10. Reed, D.R.; Hayashi, M.; Wagner, L.; Binitie, O.; Steppan, D.A.; Brohl, A.S.; Shinohara, E.T.; Bridge, J.A.; Loeb, D.M.; Borinstein, S.C.; Isakoff, M.S. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer, 2017, 123(12), 2206-2218. doi: 10.1002/cncr.30589 PMID: 28323337
  11. Judson, I.; Verweij, J.; Gelderblom, H.; Hartmann, J.T.; Schöffski, P.; Blay, J.Y.; Kerst, J.M.; Sufliarsky, J.; Whelan, J.; Hohenberger, P.; Krarup-Hansen, A.; Alcindor, T.; Marreaud, S.; Litière, S.; Hermans, C.; Fisher, C.; Hogendoorn, P.C.W.; dei Tos, A.P.; van der Graaf, W.T.A. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol., 2014, 15(4), 415-423. doi: 10.1016/S1470-2045(14)70063-4 PMID: 24618336
  12. Yetkin-Arik, B.; Kastelein, A.W.; Klaassen, I.; Jansen, C.H.J.R.; Latul, Y.P.; Vittori, M.; Biri, A.; Kahraman, K.; Griffioen, A.W.; Amant, F.; Lok, C.A.R.; Schlingemann, R.O.; van Noorden, C.J.F. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. Biochim. Biophys. Acta Rev. Cancer, 2021, 1875(1), 188446. doi: 10.1016/j.bbcan.2020.188446 PMID: 33058997
  13. Tan, H.W.; Xu, Y.M.; Qin, S.H.; Chen, G.F.; Lau, A.T.Y. Epigenetic regulation of angiogenesis in lung cancer. J. Cell. Physiol., 2021, 236(5), 3194-3206. doi: 10.1002/jcp.30104 PMID: 33078404
  14. Li, S. Anlotinib: A novel targeted drug for bone and soft tissue sarcoma. Front. Oncol., 2021, 11, 664853. doi: 10.3389/fonc.2021.664853 PMID: 34094958
  15. Zhang, L.; Sun, S.; Wang, Y.; Mo, Y.; Xiong, F.; Zhang, S.; Zeng, Z.; Xiong, W.; Li, G.; Chen, H.; Guo, C. Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway. Am. J. Cancer Res., 2020, 10(3), 870-883. PMID: 32266096
  16. Jiang, X. The role of microenvironment in tumor angiogenesis. J. Exper. Clini. Canc. Res., 2020, 39(1), 204.
  17. Campochiaro, P.A.; Akhlaq, A. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Prog. Retin. Eye Res., 2021, 83, 100921. doi: 10.1016/j.preteyeres.2020.100921 PMID: 33248215
  18. Shen, G.; Zheng, F.; Ren, D.; Du, F.; Dong, Q.; Wang, Z.; Zhao, F.; Ahmad, R.; Zhao, J. Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol., 2018, 11(1), 120. doi: 10.1186/s13045-018-0664-7 PMID: 30231931
  19. Bleloch, J.S.; Ballim, R.D.; Kimani, S.; Parkes, J.; Panieri, E.; Willmer, T.; Prince, S. Managing sarcoma: Where have we come from and where are we going? Ther. Adv. Med. Oncol., 2017, 9(10), 637-659. doi: 10.1177/1758834017728927 PMID: 28974986
  20. Sun, Y.; Niu, W.; Du, F.; Du, C.; Li, S.; Wang, J.; Li, L.; Wang, F.; Hao, Y.; Li, C.; Chi, Y. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J. Hematol. Oncol., 2016, 9(1), 105. doi: 10.1186/s13045-016-0332-8 PMID: 27716285
  21. Meyer, M.; Seetharam, M. First-line therapy for metastatic soft tissue sarcoma. Curr. Treat. Options Oncol., 2019, 20(1), 6. doi: 10.1007/s11864-019-0606-9 PMID: 30675651
  22. Abrahams, C.; Woudberg, N.J.; Lecour, S. Anthracycline-induced cardiotoxicity: Targeting high-density lipoproteins to limit the damage? Lipids Health Dis., 2022, 21(1), 85. doi: 10.1186/s12944-022-01694-y PMID: 36050733
  23. Tan, R.; Cong, T.; Xu, G.; Hao, Z.; Liao, J.; Xie, Y.; Lin, Y.; Yang, X.; Li, Q.; Liu, Y.; Xia, Y.L. Anthracycline-induced atrial structural and electrical remodeling characterizes early cardiotoxicity and contributes to atrial conductive instability and dysfunction. Antioxid. Redox Signal., 2022, 37(1-3), 19-39. doi: 10.1089/ars.2021.0002 PMID: 35081742
  24. van der Graaf, W.T.A.; Blay, J.Y.; Chawla, S.P.; Kim, D.W.; Bui-Nguyen, B.; Casali, P.G.; Schöffski, P.; Aglietta, M.; Staddon, A.P.; Beppu, Y.; Le Cesne, A.; Gelderblom, H.; Judson, I.R.; Araki, N.; Ouali, M.; Marreaud, S.; Hodge, R.; Dewji, M.R.; Coens, C.; Demetri, G.D.; Fletcher, C.D.; Dei Tos, A.P.; Hohenberger, P. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2012, 379(9829), 1879-1886. doi: 10.1016/S0140-6736(12)60651-5 PMID: 22595799
  25. Mir, O.; Brodowicz, T.; Italiano, A.; Wallet, J.; Blay, J.Y.; Bertucci, F.; Chevreau, C.; Piperno-Neumann, S.; Bompas, E.; Salas, S.; Perrin, C.; Delcambre, C.; Liegl-Atzwanger, B.; Toulmonde, M.; Dumont, S.; Ray-Coquard, I.; Clisant, S.; Taieb, S.; Guillemet, C.; Rios, M.; Collard, O.; Bozec, L.; Cupissol, D.; Saada-Bouzid, E.; Lemaignan, C.; Eisterer, W.; Isambert, N.; Chaigneau, L.; Cesne, A.L.; Penel, N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol., 2016, 17(12), 1732-1742. doi: 10.1016/S1470-2045(16)30507-1 PMID: 27751846
  26. Zhang, R.S.; Liu, J.; Deng, Y.T.; Wu, X.; Jiang, Y. The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the POST‐ALTER0203 trial era. Cancer Med., 2022, 11(11), 2271-2283. doi: 10.1002/cam4.4613 PMID: 35191609
  27. Liu, Z.; Gao, S.; Zhu, L.; Wang, J.; Zhang, P.; Li, P.; Zhang, F.; Yao, W. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study. Cancer Med., 2021, 10(21), 7593-7600. doi: 10.1002/cam4.4286 PMID: 34564939
  28. Colosia, A.; Khan, S.; Hackshaw, M.D.; Oglesby, A.; Kaye, J.A.; Skolnik, J.M. A systematic literature review of adverse events associated with systemic treatments used in advanced soft tissue sarcoma. Sarcoma, 2016, 2016, 1-13. doi: 10.1155/2016/3597609 PMID: 27516726
  29. Li, J.; Han, B.; Liu, H. Outcomes of anlotinib maintenance therapy in patients with advanced NSCLC in a real-world setting. Front. Oncol., 2022, 12, 785865. doi: 10.3389/fonc.2022.785865 PMID: 35847883
  30. Cai, M.; Zhu, J.; Zhou, G. Efficacy and safety of treating refractory bone and soft tissue sarcoma with anlotinib in different treatment patterns. Comput. Math. Methods Med., 2022, 2022, 1-10. doi: 10.1155/2022/3287961 PMID: 35991143

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bentham Science Publishers